Cogent Biosciences
COGT
267 hedge funds and large institutions have $6.18B invested in Cogent Biosciences in 2025 Q4 according to their latest regulatory filings, with 95 funds opening new positions, 93 increasing their positions, 64 reducing their positions, and 21 closing their positions.
352% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 21
170% more capital invested
Capital invested by funds: $2.29B → $6.18B (+$3.9B)
108% more funds holding in top 10
Funds holding in top 10: 12 → 25 (+13)
45% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 64
37% more funds holding
Funds holding: 195 → 267 (+72)
28% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $18.6M
17.58% less ownership
Funds ownership: 139.85% → 122.27% (-18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$116M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$106M |
| 3 |
BlackRock
New York
|
+$73.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$69.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$142M |
| 2 |
VA
VR Adviser
New York
|
-$56.2M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$48.4M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$45.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$44.7M |
COGT Hedge Fund Activity: Q4 2025 in Review
267 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2025, worth a combined $6.18B — up 170% from $2.29B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new COGT positions and 21 closed out — a net gain of 74 holders — while 93 added to existing stakes and 64 trimmed.
The largest buyer was RTW Investments, adding an estimated $116M. The largest seller was Commodore Capital, cutting an estimated $142M.
- 267 institutional investors held Cogent Biosciences (COGT) as of Q4 2025, up from 195 in Q3 2025.
- Funds reported $6.18B of Cogent Biosciences stock for Q4 2025, up 170% quarter-over-quarter.
- 95 funds opened new Cogent Biosciences positions in Q4 2025 and 21 closed out, a net change of +74 holders.
- The largest Cogent Biosciences buyer in Q4 2025 was RTW Investments, an estimated $116M added.
- The largest Cogent Biosciences seller in Q4 2025 was Commodore Capital, an estimated $142M sold.
Based on aggregated 13F filings for Q4 2025.